LBM-415: Antibacterial peptide deformylase inhibitor

Drugs of the Future

Volumn 30, Issue 1, 2005, Pages 23-28

  McIntyre, J A ^a   Castaner J ^a   Martin L ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; ANTIINFECTIVE AGENT; CEFTRIAXONE; CIPROFLOXACIN; CLARITHROMYCIN; LINEZOLID; METICILLIN; N (5 FLUORO 1 OXIDO 2 PYRIDINYL) 1 [2 (N FORMYL N HYDROXYAMINOMETHYL)HEXANOYL]PROLINAMIDE; N (5 FLUORO 1 OXIDOPYRIDIN 2 YL) 1 [2 (N FORMYL N HYDROXYAMINOMETHYL)HEXANOYL]PROLINAMIDE; PENICILLIN G; PEPTIDE DEFORMYLASE INHIBITOR; TETRACYCLINE; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; CLINICAL TRIAL; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SYNTHESIS; ENTEROCOCCUS; HELICOBACTER PYLORI; HUMAN; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTIPLE DRUG DOSE; MYCOPLASMA PNEUMONIAE; NONHUMAN; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PNEUMONIA; RESPIRATORY TRACT INFECTION; SINGLE DRUG DOSE; SKIN INFECTION; STAPHYLOCOCCUS; STREPTOCOCCUS; STREPTOCOCCUS PNEUMONIAE;

EID: 14944375645     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2005.030.01.871650     Document Type: Article

References (38)

1. Patel, D.V., Yuan, Z., Jain, R.K., Garcia Alvarez, S., Jacobs, J. (Vicuron Pharmaceuticals Inc.; Novartis AG). N-Formyl hydroxylamine cpds. as inhibitors of PDF. CA 2448526, EP 1401828, US 2003045479, WO 02102790.
2. Livermore, D.M. Bacterial resistance: Origins, epidemiology, and impact. Clin Infect Dis 2003, 36(Suppl. 1.): S11-23.
3. Giglione, C., Pierre, M., Meinnel, T. Peptide deformylase as a target for new generation, broad spectrum antimicrobial agents. Mol Microbiol 2000, 36: 1197-205.
4. Waller, A.S., Clements, J.M. Novel approaches to antimicrobial therapy: Peptide deformylase. Curr Opin Drug Discov Dev 2002, 5: 785-92.
5. Jones, R.N., Fritsche, T.R., Sader, H.S. Antimicrobial spectrum and activity of NVP PDF-713, a novel peptide deformylase inhibitor, tested against 1,837 recent Gram-positive clinical isolates. Diagn Microbiol Infect Dis 2004, 49: 63-5.
6. Jones, R.N., Fritsche, T., Sader, H. Antimicrobial spectrum and activity of NVP PDF-713 (PDF7), a novel peptide deformylase inhibitor, tested against 1,837 recent Gram-positive clinical isolates. Clin Microbiol Infect 2004, 10(Suppl. 3): Abst P914.
7. Fritsche, T.R., Rhomberg, P.R., Jones, R.N. Comparative antimicrobial characterization of LBM415 (NVP PDF-713), a new peptide deformylase inhibitor (PDI). 44th Intersci Conf Antimicrob Agents Chemother (Oct 30-Nov 2, Washington DC) 2004, Abst F-1961.
8. Lopez, S., Wu, C., Blais, J. et al. In vitro profiling of the new peptide deformylase inhibitor LBM415 (VIC-104959). 44th Intersci Conf Antimicrob Agents Chemother (Oct 30-Nov 2, Washington DC) 2004, Abst F-1960.
9. Ryder, N.S., Dzink-Fox, J., Kubik, B. et al. LBM415, a new peptide deformylase inhibitor with potent in vitro activity against drug-resistant bacteria. 44th Intersci Conf Antimicrob Agents Chemother (Oct 30-Nov 2, Washington DC) 2004, Abst F-1959.
10. Credito, K., Lin, G., Ednie, L.M., Appelbaum, P.C. Antistaphylococcal activity of LBM415, a new peptide deformylase inhibitor, compared with those of other agents. Antimicrob Agents Chemother 2004, 48: 4033-6.
11. Appelbaum, P., Ednie, L., Jacobs, M. Antistaphylococcal activity of NVP-PDF713, a new peptide deformylase inhibitor compared to other agents. Clin Microbiol Infect 2004, 10(Suppl. 3): Abst P915.
12. Appelbaum, P., Credito, K., Lin, G., Jacobs, M. Time-kill study of antistaphylococcal activity of NVP PDF-713 compared to other agents. Clin Microbiol Infect 2004, 10(Suppl. 3): Abst P919.
13. Bozdogan, B., Esel, D., Whitener, C., Browne, F.A., Appelbaum, P.C. Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center. J Antimicrob Chemother 2003, 52: 864-8.
14. Bozdogan, B., Esel, D., Appelbaum, P.C. Activity of oxazolidinones, DNA nanobinders and peptide deformylase (PDF) inhibitors against a vancomycin resistant Staphylococcus aureus (VRSA). 43rd Intersci Conf Antimicrob Agents Chemother (Sept 14-17, Chicago) 2003, Abst F-1471.
15. Ednie, L.M., Pankuch, G., Appelbaum, P.C. Antipneumococcal activity of LBM415, a new peptide deformylase inhibitor, compared with those of other agents. Antimicrob Agents Chemother 2004, 48: 4027-32.
16. Appelbaum, P., Ednie, L., Jacobs, M. Antipneumococcal activity of NVP-PDF713 compared to 18 other agents. Clin Microbiol Infect 2004, 10(Suppl. 3): Abst P916.
17. Appelbaum, P., Pankuch, G., Jacobs, M. Time-kill study of the antipneumococcal activity of NVP PDF-713, a new peptide deformylase inhibitor, compared to 13 other agents. Clin Microbiol Infect 2004, 10(Suppl. 3): Abst P920.
18. Snydman, D.R., Jacobus, N.V., McDermott, L.A. Evaluation of the in vitro activity of NVP PDF-713 against clinical anaerobic isolates with emphasis on the Bacteroides fragilis group. Clin Microbiol Infect 2004, 10(Suppl. 3): Abst P917.
19. Jones, R., Moet, G., Sader, H., Pritsche, T. Potential utility of a peptide deformylase inhibitor, NVP PDF-713 (PDF7) against oxazolidinone- resistant or streptogramin-resistant Gram-positive isolates. Clin Microbiol Infect 2004, 10(Suppl. 3): Abst P918.
20. Fritsche, T.R., Jones, R.N. Antimicrobial activity of LBM 415 (NVP PDF-713) tested against Neisseria meningitidis (NM) and N. gonorrhoeae (NG). 44th Intersci Conf Antimicrob Agents Chemother (Oct 30-Nov 2, Washington DC) 2004, Abst F-1962.
21. Waites, K.B., Crabb, D.M., Duffy, L.B. Comparative in vitro activities of an investigational peptide deformylase inhibitor LBM-415 and other agents against mycoplasmas and ureaplasmas of human origin. 44th Intersci Conf Antimicrob Agents Chemother (Oct 30-Nov 2, Washington DC) 2004, Abst E-2050.
22. Bell, J.M., Turnidge, J.D., Inoue, M., Kohno, S., Hirakata, Y., Ono, Y. Activity of a peptide deformylase inhibitor (NVP PDF-713) against isolates from Japan. 44th Intersci Conf Antimicrob Agents Chemother (Oct 30-Nov 2, Washington DC) 2004, Abst E-2049.
23. Fonseca-Aten, M., Rios, A.M., Mejias, A., Chavez-Bueno, S., Gomez, A.M., McCracken, G.H., Hardy, R.D. Evaluation of NVP-PDF713 for the treatment of experimental Mycoplasma pneumoniae pneumonia. 44th Intersci Conf Antimicrob Agents Chemother (Oct 30-Nov 2, Washington DC) 2004, Abst F-1966.
24. Neckermann, G., Yu, D., Manni, K. et al. LBM415, a new oral peptide deformlyase inhibitor: Efficacy in murine infection models. 44th Intersci Conf Antimicrob Agents Chemother (Oct 30-Nov 2, Washington DC) 2004, Abst F-1964.
25. Wang, W., Wu, C., White, R., Yuan, Z. Proteomic study of peptide deformylase inhibition in Streptococcus pneumoniae and Staphylococcus aureus. 44th Intersci Conf Antimicrob Agents Chemother (Oct 30-Nov 2, Washington DC) 2004, Abst F-1541.
26. Leeds, J.A., Dean, C.R., Favre, B., Dzink-Fox, J., Sachdeva, M., Narayan, S., Medeiros, J., Ryder, N.S. In vitro selection of decreased susceptibility to the novel peptide deformylase inhibitor LBM415 in three pathogens. 44th Intersci Conf Antimicrob Agents Chemother (Oct 30-Nov 2, Washington DC) 2004, Abst C1-1880.
27. Dean, C.R., Narayan, S., Dzink-Fox, J., Puyang, X., Ryder, N.S. Role of efflux in decreasing susceptibility to the peptide deformylase inhibitor LBM415 in Haemophilus influenzae. 44th Intersci Conf Antimicrob Agents Chemother (Oct 30-Nov 2, Washington DC) 2004, Abst C1-1881.
28. Chen, D., Tembe, V., Cramer, J. et al. LBM415 (VIC-104959), a novel peptide deformylase inhibitor with favorable pharmacokinetic profile in rodents. 44th Intersci Conf Antimicrob Agents Chemother (Oct 30-Nov 2, Washington DC) 2004, Abst F-1965.
29. Osborne, C.S., Neckermann, G., Goldovitz, J. et al. Pharmacodynamics of LBM415, a new peptide deformylase inhibitor, in the neutropenic mouse thigh infection model. 44th Intersci Conf Antimicrob Agents Chemother (Oct 30-Nov 2, Washington DC) 2004, Abst F-1963.
30. Craig, W., Andes, D. In vivo pharmacodynamics of NVP-PDF-713, a new peptide deformylase inhibitor. Clin Microbiol Infect 2004, 10(Suppl. 3): Abst P921.
31. Craig, W., Andes, D. In vivo pharmacodynamic activity of NVP-PDF-713 against multiple bacterial pathogens. Clin Microbiol Infect 2004, 10(Suppl. 3): Abst P922.
32. Sun, H., MacLeod, C., Zheng, W., Dobson, C., Skerjanec, A. Single and multiple dose pharmacokinetics of LBM415, a novel peptide deformylase (PDF) inhibitor. 33rd Annu Meet Amer Coll Clin Pharmacol (Oct 3-5, Phoenix) 2004, Abst 30.
33. Preclinical characterization and pharmacokinetics of a novel peptide deformylase inhibitor, LBM415. DailyDrugNews.com (Daily Essentials) November 23, 2004.
34. Anderegg, T.R., Jones, R.N., Quality Control Working Group. Disk diffusion quality control guidelines for NVP-PDF 713: A novel peptide deformylase inhibitor. Diagn Microbiol Infect Dis 2004, 48: 55-7.
35. Fritsche, T., Anderegg, T., Jones, R. Determination of quality control guidelines for MIC dilution and disk diffusion methods when testing NVP-PDF713, a novel peptide deformylase inhibitor. Clin Microbiol Infect 2004, 10(Suppl. 3): Abst P923.
36. Anderegg, T.R., Biedenbach, D.J., Jones, R.N., Quality Control Working Group. Quality control guidelines for MIC susceptibility testing of NVP PDF-713: A novel peptide deformylase inhibitor. Int J Antimicrob Agents 2003, 22: 84-6.
37. Fritsche, T.R., Rhomberg, P.R., Jones, R.N. Comparisons of inter-method susceptibility testing accuracy for LBM415 (NVP PDF-713) using 2,625 recent clinical isolates. 44th Intersci Conf Antimicrob Agents Chemother (Oct 30-Nov 2, Washington DC) 2004, Abst D-1919.
38. Moet, G., Jones, R., Rhomberg, P., Fritsche, T. Determination of dry-form commercial reagent reproducibility and MIC validations for NVP-PDF713, a novel peptide deformylase inhibitor. Clin Microbiol Infect 2004, 10(Suppl. 3): Abst P924.